Related Experiment Video
Updated: Mar 20, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Utility of Plasmapheresis in Autoimmune-Mediated Encephalopathy in Children: Potentials and Challenges
1Department of Pediatrics, Division of Pediatric Neurology, Hamad Medical Corporation, Doha, Qatar.
Insights
Plasmapheresis may be a beneficial first-line therapy for pediatric autoimmune encephalopathy, though its use requires careful consideration of indications and logistics. This review examines its clinical value in children.
Area of Science:
- Pediatric Neurology
- Immunology
- Critical Care Medicine
Background:
- Autoimmune-mediated encephalopathy in children presents significant diagnostic and therapeutic challenges.
- Current pediatric literature infrequently evaluates plasmapheresis for this condition.
- Children with these encephalopathies require specialized intensive care and neurological services.
Purpose of the Study:
- To review current knowledge on the clinical value of plasmapheresis in children with immune-mediated encephalopathy.
- To highlight plasmapheresis as a potentially beneficial first-line therapy.
- To address challenges in the indications, value, and logistics of plasmapheresis.
Main Methods:
- Literature review of current knowledge.
- Analysis of clinical utility and usefulness of plasmapheresis.
- Examination of indications, value, logistics, and procedural difficulties.
Main Results:
- Plasmapheresis is an emerging therapy with potential benefits for pediatric autoimmune encephalopathy.
- Its utility and usefulness in this specific pediatric population are not well-established in current literature.
- Challenges related to indications, value, and logistics are frequently encountered.
Conclusions:
- Early immunotherapy is crucial for improving outcomes in children with immune-mediated encephalopathy.
- Plasmapheresis warrants further investigation as a potential first-line treatment.
- Addressing practical challenges is key to optimizing plasmapheresis use in pediatric cases.
Abstract:
Autoimmune-mediated encephalopathy in children continues to constitute a diagnostic and therapeutic challenge in pediatric population. Utility and usefulness in this clinical setting of plasmapheresis have seldom been evaluated in current pediatric literature. Children with immune-mediated encephalopathies represent a uniquely different group among patients presenting to intensive care units or neurological services worldwide. Arriving at a final diagnosis is not an easy task for treating physicians. It is very crucial to consider early use of first-line immunotherapy modalities, save those children's lives and improve outcomes. Plasmapheresis is an emerging, potentially beneficial first-line therapy in such patients. However, indications, value, logistics, and procedural difficulties are often faced. This study is mainly meant to review the current knowledge in regard to the clinical value of plasmapheresis in children with immune-mediated encephalopathy.
